Gamma to acquire majority stake in Mirus Bio

By The Science Advisory Board staff writers

May 18, 2021 -- Gamma Biosciences has purchased a controlling stake in Mirus Bio, a developer of lipid-polymer nanocomplexes for nucleic acid delivery.

The deal expands Gamma Biosciences' reach in gene therapy and next-generation vaccines, while supporting the launch of Mirus Bio's flagship TransIT VirusGen platform for manufacturing of adeno-associated viruses (AAV) and lentivirus-based viral vectors for gene therapy. The investment will also help to further develop and commercialize TransIT VirusGen for in vivo delivery applications, according to the companies.

Terms of the agreement were not disclosed.

Gamma Biosciences to acquire BioMagnetic Solutions
Gamma Biosciences has agreed to acquire BioMagnetic Solutions, a next-generation cell selection and bioseparation technology company.
Gamma announces Astrea, Avacta partnership
Life sciences firm Gamma Biosciences has announced a licensing agreement between chromatography developer Astrea Bioseparations and biotherapeutic and...
Gamma Biosciences acquires Nanopareil
Gamma Biosciences has purchased nanofiber membrane product developer Nanopareil.

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter